MYC and lymphoma: Further study revealed that cotreatment of JQ1 and anti-PD-L1 antibody synergistically suppressed MYC-driven lymphoma in mice56, indicating that JQ1 is a potential adjuvant that could enhance the efficacy of immune checkpoint inhibitors.